Product menu

image of a woman with shingles rash on her back

Shingles pain can be severe, disabling, and last for weeks

  • Up to 90% of immunocompetent individuals experience acute local neurological pain during the eruptive phase.1
  • Immunocompromised patients may be more likely to experience atypical and/or more severe disease and complications.2

SHINGRIX is not indicated for the treatment of HZ or its complications, such as pain.

Do your patients 50 years and older know they are at risk?

  • Patients aged ≥50 years are at risk for shingles, even if they have a healthy lifestyle.3
  • Age-related decline in immunity was shown to be the dominant driver of shingles.3

LEARN MORE

Immunocompromised risk factors

  • In a pooled analysis, the risk of developing HZ was studied across a number of immunocompromised risk factors vs. control.4

LEARN MORE

Graph icon

Efficacy data for SHINGRIX1

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.1

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
Checkmark icon

SHINGRIX: Recommendations from NACI

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI).2

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  3. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
  4. Marra F, et al. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis 2020;7(1):ofaa005.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24